A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with atezolizumab or isatuximab alone in patients with advanced malignancies

Sanofi-aventis recherche & développement0 个研究点目标入组 385 人开始时间: 2018年6月1日最近更新: 2022年5月30日

适应症

试验速览

暂无简介。

•- Patients must have a known diagnosis of either unresectable hepatocellular carcinoma (HCC), platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN), platinum-resistant/refractory epithelial ovarian cancer (EOC) with evidence of measurable disease
•or recurrent glioblastoma multiforme (GBM).
•- =18 years of age.
•-For patients with HCC: Documentation of progressive disease (PD) during or after treatment with either sorafenib or lenvatinib, or intolerance to the therapy.
•-For patients with SCCHN: Received and failed up to 2 lines of prior systemic anti-cancer therapy with documentation of tumor recurrence or PD within 6 months of last platinum-based therapy in primary, recurrent, or metastatic setting.
•-For patients with EOC: Received and failed up to 3 lines of prior platinum-containing therapy when the disease was platinum-sensitive, and the patients should not have received any systemic therapy for platinum-resistant/refractory disease.
•-For patients with GBM: Documentation of PD or first recurrence during or after temozolomide maintenance therapy for newly diagnosed GBM treated with 1st line radiotherapy plus concurrent temozolomide.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 289
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 96

•- Prior exposure to agent that blocks CD38 or participation in clinical studies with isatuximab
•- For patients with HCC, SCCHN, EOC or GBM prior exposure to any agent (approved or investigational) that blocks the PD-1/PD-L1 pathway.
•- Evidence of other immune related disease /conditions.
•- History of non-infectious pneumonitis requiring steroids or current pneumonitis; history of the thoracic radiation.
•- Has received a live-virus vaccination within 28 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.
•- Prior solid organ or bone marrow transplantation.
•- Eastern Cooperative Oncology Group performance status (PS) =2 for patients with HCC, SCCHN or EOC or Karnofsky performance score = 70 for patients with GBM
•- Poor bone marrow reserve.
•- Poor organ function.

发起方